ANNOUNCEMENT

As on (19 Jan 2021 | 01:47)
Tata Coffee

Tata Coffee has revised the meeting of the Board of Directors which was scheduled to be held on 28 January 2021.The meeting will now be held on 27 January 2021.

Dharamsi Morarji

Dharamsi Morarji Chemicals Company will hold a meeting of the Board of Directors of the Company on 8 February 2021.

Indo Gulf Inds.

Indo Gulf Industries will hold a meeting of the Board of Directors of the Company on 13 February 2021.

Reliance Industr

Reliance Industries will hold a meeting of the Board of Directors of the Company on 22 January 2021.

Sundaram Finance

Sundaram Finance will hold a meeting of the Board of Directors of the Company on 20 January 2021.

SML ISUZU

SML Isuzu will hold a meeting of the Board of Directors of the Company on 5 February 2021.

Tata Consumer

Tata Consumer Products will hold a meeting of the Board of Directors of the Company on 2 February 2021.

Triveni Glass

Triveni Glass will hold a meeting of the Board of Directors of the Company on 25 January 2021.

Dr Reddy's Labs

Dr. Reddys Laboratories announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.

The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.

Earlier, the Data and Safety Monitoring Board (DSMB) reviewed the safety data from the phase 2 clinical trial of the vaccine and recommended the phase 3 recruitment. In its report, the DSMB concluded that no safety concerns were identified and the study met the primary endpoints of safety.

In September 2020, Dr. Reddy's partnered with Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V vaccine and for its distribution rights in India.

Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the established human adenoviral vector platform. The vaccine's efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials in Russia. Currently, the vaccine's clinical trials are underway in the UAE, Egypt, Venezuela and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia and Serbia for inoculation.

Visaka Industrie

Visaka Industries will hold a meeting of the Board of Directors of the Company on 28 January 2021.